# US 6,730,498 B1 · Production of functional proteins: balance of shear stress and gravity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,498 B1
- Document ID: US6730498B1
- Status: Granted
- Kind: B1
- Application number: 09/056,363
- Filed: 1998-04-07
- Granted: 2004-05-04
- Earliest claimed: 1997-04-08
- Assignees: The United States of America as represented by the Administrator of the National Aeronautics and Space Administration
- Inventors: Thomas John Goodwin; Timothy Grant Hammond; James Howard Kaysen
- Web page: https://patentgrep.com/patent/US6730498B1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 15/67: General methods for enhancing the expression
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/13: Decoys
- C12N 2310/315: Phosphorothioates
- C12N 2501/60: Transcription factors
- C12N 2510/02: Cells for production
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a method for production of functional proteins including hormones by renal cells in a three dimensional co-culture process responsive to shear stress using a rotating wall vessel. Natural mixture of renal cells expresses the enzyme 1-a-hydroxylase which can be used to generate the active form of vitamin D: 1,25-diOH vitamin D3. The fibroblast cultures and co-culture of renal cortical cells express the gene for erythropoietin and secrete erythropoietin into the culture supernatant. Other shear stress response genes are also modulated by shear stress, such as toxin receptors megalin and cubulin (gp280). Also provided is a method of treating in-need individual with the functional proteins produced in a three dimensional co-culture process responsive to shear stress using a rotating wall vessel.

## Claims

### Claim 1

A method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions comprising the steps of:
selecting mammalian cells for cell culture wherein said cells are capable of producing at least one functional biomolecule selected from the group consisting of functional proteins, non-peptide hormones, vitamins and mixtures thereof;
isolating the selected mammalian cells for introduction into the cell culture;
placing the mammalian cells into a rotating wall vessel containing a culture media and a culture matrix;
producing three dimensional cell aggregates under simulated micro gravity culture conditions; and
separating at least one functional biomolecule expressed by the cell culture.

### Claim 2 (depends on 1)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 1 further comprising separating the functional biomolecule from a source selected from the group consisting of lysed cells, the culture media and mixtures thereof.

### Claim 3 (depends on 1)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions and detecting their production of claim 1 wherein the biomolecule is selected from the group consisting of a hormone, a toxin receptor and a shear stress dependent functional biomolecule not associated with a degenerative cell process and isolating the selected functional biomolecule.

### Claim 4 (depends on 1)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 1 wherein the functional biomolecule is selected from the group consisting of magnesium dependent superoxide dismutase, nitric synthase, c-fos, c-jun, platelet derived growth factor-b, transforming growth factor-b, tissue-type plasminogen activator, monocyte chemotactic protein-1, megalin, cubulin, erythropoietin 1-α-hydroxylase and 1,25-dihydroxy-vitamin D 3.

### Claim 5 (depends on 1)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 1 wherein said mammalian cells are selected from the group consisting of epithelial cells, endothelial cells and mixtures thereof capable of producing functional biomolecules.

### Claim 6 (depends on 1)

The method of producing a biomolecule in a bioreactor under mulated microgravity culture conditions of claim 1, wherein said culture matrix is micro carrier beads.

### Claim 7 (depends on 1)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 1 wherein said mammalian cells are organ cells capable of producing functional biomolecules selected from the group consisting of renal cortical cells, hepatocytes, pancreatic islets, renal interstitial cells, renal fibroblast cells, parathyroid cells, thyroid cells, pituitary cells, ovarian cells and testicular cells.

### Claim 8 (depends on 5)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 5 wherein the functional biomolecules are suitable for therapeutic use.

### Claim 9 (depends on 7)

The method of producing biomolecules in a bioreactor under simulated microgravity culture conditions of claim 7 wherein the functional biomolecules are suitable for therapeutic use.

### Claim 10 (depends on 5)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 5 wherein the mammalian cells are human cells.

### Claim 11 (depends on 5)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 5 wherein the organ cells are human organ cells.

### Claim 12 (depends on 1)

The method of producing biomolecules in a bioreactor under simulated microgravity culture conditions of claim 1 further comprising the steps of:
selecting mammalian cells capable of producing erythropoietin;
culturing the mammalian cells under conditions to produce erythropoietin;
collecting the culture media and cells; and
separating the erythropoietin from the source consisting of the group of culture media, lysed cells and mixtures thereof.

### Claim 13 (depends on 12)

The method of claim 12 further purifying erythropoietin wherein the erythropoietin is suitable for human therapeutic use.

### Claim 14 (depends on 1)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 1 further comprising the steps of:
selecting mammal cells capable of producing 1,25-dihydroxy-vitamin D 3;
culturing the cells under conditions to produce 1,25-dihydroxy-vitamin D 3;
collecting the cells;
lysing the cells; and
separating the 1,25-dihydroxy-vitamin D 3.

### Claim 15 (depends on 14)

The method of claim 14 of producing and purifying I, 25-dihydroxy-vitamin D 3 in a bioreactor under simulated microgravity culture conditions wherein the 1,25-dihydroxy-vitamin D 3 is suitable for human therapeutic use.

### Claim 16 (depends on 1)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 1 wherein the isolated functional biomolecules are suitable for therapeutic use.

### Claim 17 (depends on 1)

The method of producing a biomolecule in a bioreactor under simulated microgravity culture conditions of claim 1 wherein the functional biomolecules are suitable for diagnostic use.
